The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2013

Filed:

Dec. 15, 2009
Applicants:

Aqeel Fatmi, Greensboro, NC (US);

Tae Kyoung Kim, High Point, NC (US);

Karla E. Madrigal, High Point, NC (US);

Inventors:

Aqeel Fatmi, Greensboro, NC (US);

Tae Kyoung Kim, High Point, NC (US);

Karla E. Madrigal, High Point, NC (US);

Assignee:

Banner Pharmacaps, Inc., High Point, NC (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2006.01);
U.S. Cl.
CPC ...
A61K 9/14 (2013.01); A61K 9/16 (2013.01); A61K 9/1658 (2013.01); A61K 9/48 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01);
Abstract

Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.


Find Patent Forward Citations

Loading…